Vanda slides after drug fails PhII/III for depression

Shares of Vanda Pharmaceuticals ($VNDA) took a hit this morning after the biotech said that tasimelteon had failed a Phase II/III study for depression. The drug performed just about as well as a placebo, a common occurrence in the depression R&D field. The biotech says it is dumping its depression program, noting that the drug recently posted upbeat results for non-24-hour disorder, a rare sleep disease. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.